pharma · Major Depressive Disorder (MDD) · Primary or advanced breast cancer LumA or ER+ Lobular subtypes.
Talon Biomarkers
Talion
Talon Biomarkers clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Whippany, USA
- Founded
- 2021
- Employees
- 7
- Programs
- 5
- Drugs
- 44
- Patents
- 0
Talon Biomarkers projects
5 ClinicalTrials.gov programs sponsored by Talon Biomarkers.
Talon Biomarkers has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
PRIN - 20227EA9AN
Talion
Major Depressive Disorder (MDD)
1 trial -
PRIN - 20227EA9AN
Talion
Major Depressive Disorder (MDD)
1 trial -
-
Talion
Primary or advanced breast cancer LumA or ER+ Lobular subtypes.
1 trial -
CIBI3009A101
Talion
Extensive-Stage Small Cell Lung Cancer
1 trial -
Hyperbolic
Talion
non-small cell lung cancer (NSCLC)
1 trial
Frequently asked questions
How many clinical projects does Talon Biomarkers have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.